UPDATE: Credit Suisse Raises PT to $44 on Forest Laboratories on Positive Linzess Survey
Credit Suisse maintained Forest Laboratories (NYSE: FRX) with an Outperform rating and raised the price target from $42.00 to $44.00.
Credit Suisse analyst Catherine Arnold noted, "Credit Suisse proprietary market research survey with approx. 100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs of which ~70% early Linzess users and all with brand awareness."
Forest Laboratories closed at $37.93 on Thursday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.